TBX1 and chordoma: Previous studies found that Brachyury is a tumor-specific antigen in chordoma, leading to some studies designed tumor vaccines targeting this protein and conducted clinical trials accordingly, which became the beginning of research on immunotherapy of chordoma (14, 15).